Raj Rakesh, Raj Pooja Mongia, Ram Alpana
Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya Bilaspur (A Central University), Bilaspur, C.G. 495009, India.
Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya Bilaspur (A Central University), Bilaspur, C.G. 495009, India.
Eur J Pharm Sci. 2016 Jun 10;88:83-90. doi: 10.1016/j.ejps.2016.04.002. Epub 2016 Apr 7.
Leukemia is the common cause of death and worldwide incidence of this disease is increasing. Chemotherapy is the first choice for leukemia treatment, but the major limitations of standard therapy are its side effects and poor patient compliances. Therefore it is imperative to look for a therapeutic system with lesser side effects urgently to address the underlying causes of poor treatment outcomes. In such a scenario transdermal route for delivery of chemotherapeutic drugs could be a better alternative to provide sustained drug level, enhanced activity, self administration and better patient compliances. The present work is focus on the design of nanolipid based transdermal carrier, deformable liposomes bearing cytarabine as a model drug for effective delivery of drug with enhanced transdermal flux. Developed nanocarriers were characterized for their size, morphology, entrapment efficiency, skin penetration and irritation. It could be concluded that nanodeformable liposomes accentuated transdermal flux of cytarabine and could provide a new strategy for leukemia.
白血病是常见的死亡原因，且该疾病在全球的发病率正在上升。化疗是白血病治疗的首选方法，但标准疗法的主要局限性在于其副作用和患者依从性差。因此，迫切需要寻找一种副作用较小的治疗系统，以解决治疗效果不佳的根本原因。在这种情况下，化疗药物的经皮给药途径可能是一种更好的选择，可提供持续的药物水平、增强的活性、自我给药能力以及更好的患者依从性。目前的工作重点是设计基于纳米脂质的经皮载体，即负载阿糖胞苷的可变形脂质体，作为一种模型药物，用于有效递送具有增强经皮通量的药物。对所开发的纳米载体进行了尺寸、形态、包封率、皮肤渗透性和刺激性等方面的表征。可以得出结论，纳米可变形脂质体可增强阿糖胞苷的经皮通量，并可为白血病治疗提供一种新策略。
